Is this a Prime Time To acquire Elanco Animal Health Incorporated (ELAN) stock

In the latest session, Elanco Animal Health Incorporated (NYSE: ELAN) closed at $8.24 down -1.90% from its previous closing price of $8.40. In other words, the price has decreased by -$0.16 from its previous closing price. On the day, 11057960 shares were traded. ELAN stock price reached its highest trading level at $8.35 during the session, while it also had its lowest trading level at $7.90.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.



For a deeper understanding of Elanco Animal Health Incorporated’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.98. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 2.20. In the meantime, Its Debt-to-Equity ratio is 0.80 whereas as Long-Term Debt/Eq ratio is at 0.75.

Upgrades & Downgrades

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 14 when HOOVER R DAVID bought 5,000 shares for $9.55 per share. The transaction valued at 47,750 led to the insider holds 165,000 shares of the business.

HOOVER R DAVID bought 5,000 shares of ELAN for $47,288 on Mar 13. The Director now owns 160,000 shares after completing the transaction at $9.46 per share. On Mar 10, another insider, Simmons Jeffrey N, who serves as the PRESIDENT, CEO AND DIRECTOR of the company, bought 15,000 shares for $9.60 each. As a result, the insider paid 143,972 and bolstered with 45,000 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELAN now has a Market Capitalization of 4.33B and an Enterprise Value of 9.82B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.93 while its Price-to-Book (P/B) ratio in mrq is 0.54. Its current Enterprise Value per Revenue stands at 2.21 whereas that against EBITDA is 13.21.

Stock Price History:

Over the past 52 weeks, ELAN has reached a high of $24.93, while it has fallen to a 52-week low of $8.28. The 50-Day Moving Average of the stock is 9.14, while the 200-Day Moving Average is calculated to be 12.20.

Shares Statistics:

For the past three months, ELAN has traded an average of 7.67M shares per day and 7.21M over the past ten days. A total of 491.10M shares are outstanding, with a floating share count of 472.91M. Insiders hold about 0.30% of the company’s shares, while institutions hold 99.10% stake in the company. Shares short for ELAN as of May 14, 2023 were 7.85M with a Short Ratio of 7.85M, compared to 18.98M on Apr 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 1.59% and a Short% of Float of 1.94%.

Earnings Estimates

There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.06 and a low estimate of $0.03, while EPS last year was $0.36. The consensus estimate for the next quarter is $0.16, with high estimates of $0.19 and low estimates of $0.14.

Analysts are recommending an EPS of between $0.84 and $0.77 for the fiscal current year, implying an average EPS of $0.8. EPS for the following year is $0.91, with 9 analysts recommending between $1.08 and $0.75.

Revenue Estimates

A total of 7 analysts believe the company’s revenue will be $1.04B this quarter.It ranges from a high estimate of $1.05B to a low estimate of $1.02B. As of the current estimate, Elanco Animal Health Incorporated’s year-ago sales were $1.18B, an estimated decrease of -11.90% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $1.04B, an increase of 0.50% over than the figure of -$11.90% in the same quarter last year. There is a high estimate of $1.05B for the next quarter, whereas the lowest estimate is $1.02B.

A total of 8 analysts have provided revenue estimates for ELAN’s current fiscal year. The highest revenue estimate was $4.37B, while the lowest revenue estimate was $4.33B, resulting in an average revenue estimate of $4.35B. In the same quarter a year ago, actual revenue was $4.42B, down -1.50% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $4.48B in the next fiscal year. The high estimate is $4.55B and the low estimate is $4.41B. The average revenue growth estimate for next year is up 3.10% from the average revenue estimate for this year.